Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity	
Xero Limited	
ABN	
160 661 183 (ARBN)	

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

†Class of *securities issued or to be issued

Options to subscribe for Ordinary Shares in Xero Limited (**Options**)

Number of *securities issued or to be issued (if known) or maximum number which may be issued 117,500 Options (each Option, when vested, entitling the holder to subscribe for one Ordinary Share in Xero Limited, subject to the terms of the US Scheme (defined below) and the AU Plan (defined below))

3 Principal terms the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; ⁺convertible securities, the conversion price and dates for conversion)

Grant of 80,000 Options under the Xero Limited (USA) Equity Incentive Scheme (US Scheme), as remuneration and incentive for one key employee based in the United States. The Options will vest (and therefore become available for exercise) in four equal parts on each of the first four anniversaries after the date of grant, subject to the continued employment of the key employee with the Xero Limited Group on each vesting date. The Options have a final exercise date of five years from the grant date. Grant of 37,500 Options pursuant to the Xero Limited Restricted Stock Unit and Option Plan (AU) (AU Plan) to a key individual based in Australia. The Options will vest (and therefore become available for exercise) in two equal parts on 30 September 2017 and 31 March 2018, subject to the continued engagement of the key individual with the Xero Limited Group on each vesting date. The Options have a final exercise date of five years from the grant date

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

N/A

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

5 Issue price or consideration N/A. Grant of 80,000 Options pursuant to the US Scheme, as remuneration and incentive for a key employee based in the United States. Grant of 37,500 Options pursuant to the AU Plan to a key individual based in Australia. The exercise price of the Options is NZ\$19.77 per Option (being the 20 day volume weighted average market price of Xero Limited's Ordinary Shares on the NZX Main Board through to 20 April 2017)

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)

Grant of 80,000 Options under the US Scheme as remuneration and incentive for one key employee based in the United States. Grant of 37,500 Options under the AU Plan to a key individual based in Australia

6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?

N/A

If Yes, complete sections 6b -6h in relation to the *securities the subject of this Appendix 3B. and comply with section 6i

N/A

The date the security holder 6b resolution under rule 7.1A was passed

Number of *securities issued 6c without security holder approval under rule 7.1

N/A

Number of *securities issued 6d with security holder approval under rule 7.1A

N/A

6e Number of *securities issued with security holder approval under rule 7.3, or another specific holder security approval (specify date of meeting)

N/A

Number of *securities issued N/A 6f under an exception in rule 7.2

6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A	
7	⁺ Issue dates	21 April 2017 (grant d	ate)
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.		,
	Cross reference: item 33 of Appendix 3B.		
		Number	†Class
8	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in section 2 if applicable)	137,761,136	Ordinary
		Number	⁺ Class
9	Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)	2,305,501	Unlisted Options (convertible into Ordinary Shares on a 1:1 basis, subject to the terms of the relevant option plan) outstanding, taking into account all forfeited Options to date and the grant of 117,500 Options as set out in this
			Appendix 3B

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

		342,383	RSUs (a conditional contractual right to be issued up to 342,383 Ordinary Shares) outstanding, taking into account all forfeited RSUs to date
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	
Part	t 2 - Pro rata issue		
11	Is security holder approval required?	N/A	
12	Is the issue renounceable or non-renounceable?	N/A	
13	Ratio in which the *securities will be offered	N/A	
14	[†] Class of [†] securities to which the offer relates	N/A	
15	[†] Record date to determine entitlements	N/A	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A	
17	Policy for deciding entitlements in relation to fractions	N/A	
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with.	N/A	
19	Cross reference: rule 7.7. Closing date for receipt of	N/A	
.0	acceptances or renunciations	14/1	

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell part of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose	N/A
	as seeming moragine anopolog	1 777 5

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

	of their entitlements (except by sale through a broker)?	
33	⁺ Issue date	N/A
	: 3 - Quotation of sed only complete this section if you ar	
34	Type of *securities (tick one)	
(a)	*Securities described in Pa	art 1
(b)		end of the escrowed period, partly paid securities that become fully paid, s when restriction ends, securities issued on expiry or conversion of
	ies that have ticked box	. ,
Tick to docume	indicate you are providing the informants	ation or
35		ity securities, the names of the 20 largest holders of , and the number and percentage of additional olders
36		ty securities, a distribution schedule of the additional number of holders in the categories
37	A copy of any trust deed for	or the additional *securities
Entit	ies that have ticked box	34(b)
38	Number of *securities for which *quotation is sought	n
39	⁺ Class of ⁺ securities for which quotation is sought	n

40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	⁺ Class
42	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in clause 38)		

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

	N/A	
Sign here:	(Director/ Company secretary)	Date: 24 April 2017
Print name:	Chaman Sidhu	

04/03/2013 Appendix 3B Page 9

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	
Add the following:	
Number of fully paid *ordinary securities issued in that 12 month period under an exception in rule 7.2	
Number of fully paid ⁺ ordinary securities issued in that 12 month period with shareholder approval	
Number of partly paid ⁺ ordinary securities that became fully paid in that 12 month period	
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	
"A"	

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15		
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.1	
Insert number of *equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:		
Under an exception in rule 7.2		
Under rule 7.1A		
• With security holder approval under rule 7.1 or rule 7.4		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"		
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining	
"A" x 0.15		
Note: number must be same as shown in Step 2		
Subtract "C"		
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"		
	[Note: this is the remaining placement capacity under rule 7.1]	

⁺ See chapter 19 for defined terms.

04/03/2013 Appendix 3B Page II

Part 2

Rule 7.1A – Additional placem	ent capacity for eligible entities
Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
"A"	
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
Multiply "A" by 0.10	
Step 3: Calculate "E", the amount of 7.1A that has already been used Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "L placement capacity under rule 7.14	
"A" x 0.10	
Note: number must be same as shown in Step 2	
Subtract "E"	
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	
	Note: this is the remaining placement capacity under rule 7.1A

04/03/2013 Appendix 3B Page 13

⁺ See chapter 19 for defined terms.